Is bevacizumab a cost‑effective regimen for treating cerebral radiation necrosis in the United States?
-
Published:2024-08
Issue:
Volume:
Page:
-
ISSN:1879-8500
-
Container-title:Practical Radiation Oncology
-
language:en
-
Short-container-title:Practical Radiation Oncology
Author:
Lai Shufei,
Luo Shaohong,
Lin Shen,
Huang Xiaoting,
Wang Xiangzhen,
Xu Xiongwei,
Weng XiuhuaORCID
Reference45 articles.
1. Cerebral radiation necrosis: a review of the pathobiology, diagnosis and management considerations;Rahmathulla;J Clin Neurosci,2013
2. Radiation dose-volume effects in the brain;Lawrence;Int J Radiat Oncol Biol Phys,2010
3. Cerebral Radiation Necrosis: Incidence, Pathogenesis, Diagnostic Challenges, and Future Opportunities;Ali;Curr Oncol Rep,2019
4. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor;Nordal;Clin Cancer Res,2004
5. Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues;Zhuang;Mol Cancer,2019